Skip to content
Open access

The role of SAM-dependent internal m7G modification of LINC01252 in the progression of hepatocellular carcinoma

Aug 2026 · Cell Death & Disease · 0 citations

TL;DR

The findings suggest that LINC01252 functions as a SAM-dependent, m 7 G-related lncRNA, acting as a transcriptional repressor of NUPR1 and WDR4, while establishing a negative feedback loop between LINC01252 and WDR4.

Abstract

Dysregulation of long non-coding RNAs (lncRNAs) plays a significant role in the progression of hepatocellular carcinoma (HCC), yet many underlying mechanisms remain elusive. Recent studies have highlighted the critical importance of internal N 7 -methylguanosine (m 7 G) modifications in influencing RNA expression and function. In this study, we identified LINC01252, a poorly characterized lncRNA, through analyses of GEO datasets and the TCGA cohort. Notably, LINC01252 is downregulated in HCC tissues and is associated with prognostic outcomes, although the predictive value of a nomogram based on LINC01252 expression characteristics appears to be limited. Our results indicate that LINC01252 effectively inhibits tumorigenic behaviors in HCC and exerts its effects by targeting the oncogene NUPR1. Mechanistically, LINC01252 acts as an intranuclear lncRNA that binds to the NUPR1 promoter through Hoogsteen pairing, consequently inhibiting its transcriptional activity. Additionally, the internal m 7 G modification level of LINC01252 directly influences its RNA stability, contingent upon sufficient concentrations of S-adenosylmethionine (SAM), which is necessary for the activity of its key modifying enzymes, METTL1 and WDR4. Thus, LINC01252’s m 7 G modification and expression are SAM-dependent in the context of HCC. Furthermore, LINC01252 can also suppress WDR4 transcription by binding to its promoter through the same mechanism, thus inhibiting HCC progression. Our findings suggest that LINC01252 functions as a SAM-dependent, m 7 G-related lncRNA, acting as a transcriptional repressor of NUPR1 and WDR4, while establishing a negative feedback loop between LINC01252 and WDR4. However, the potential of LINC01252 as a clinical biomarker still requires further investigation.

Read PDF

Similar papers

Open access Jan 2026

Integrative Pan‐Cancer Characterization of lncRNA UPK1A‐AS1 and Its Role in Hypoxia‐Associated Sorafenib Resistance in Hepatocellular Carcinoma

It is suggested that UPK1A-AS1 is a hypoxia‐inducible oncogenic lncRNA that plays dual roles in cancer, with cancer type‐dependent associations with progression and immune modulation across malignancies and mechanistically mediating hypoxia‐associated drug resistance in HCC.

Ze-Kai Li, Min Luo, Shu-Sen Fang et al. · 0 citations

Investigating the mechanism of lncRNA SChLAP1 in prostate cancer

A mechanism wherein SChLAP1 modulates AR signaling to promote PCa growth and progression is suggested, suggesting its molecular mechanism and potential to be used as a therapeutic target or biomarker.

Zoe Coutu, Srinivas Somarowthu · 0 citations
Aug 2026

Elevated Expression of LINC02257 and LINC00659 in Breast Cancer is Associated with Poor Survival and Immune Cell Infiltration

This study found that LINC02257 and LINC00659 are upregulated in BC and are associated with malignancy-related genes and patient survival, suggesting their potential as therapeutic targets and prognostic biomarkers.

Fatemeh Badzohre, Azin Azadfekr, Farnoosh Akbari et al. · 0 citations
Open access Sep 2026

Destabilization of hsa_circ_0015508 by YTHDF2 Enhances miR-496-Mediated FOXN3 Suppression to Drive Nasopharyngeal Carcinoma Progression

A potential oncogenic pathway was delineated in which NPC migration and invasion were facilitated by YTHDF2 via degradation of circ_0015508, thereby the sponging effect of miR-496 was abolished and FOXN3 expression was suppressed.

Ai-Yu Ma, Xu Wang, Lu Lu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.